Hansen Medical Inc.
Encision co-founder resigns | Personnel Moves
AngioDynamics names senior VP & CTO | Personnel Moves
Robotics: Hansen gains 25% on $30M deal with Intuitive Surgical
Medical device moves: Marketing veep Trujillo out at Conceptus
Greatbatch proposes to mostly exit Switzerland for Indiana, Mexico | Wall Street Beat
Greatbatch (NYSE:GB) said it wants to largely shutter a pair of plants in Switzerland and relocate their operations to Ft. Wayne, Ind., and Tijuana, Mexico.
Hansen Medical sinks on FDA win for surgical robot | Wall Street Beat
Hansen Medical (NSDQ:HNSN) sank hard on Wall Street today despite announcing a vital FDA win for its Magellan surgical robot.
The device lost 4.8% as of about 3:45 p.m. today, with shares trading around $2.18.
FDA clears Hansen Medical’s Magellan surgical robot
Hansen Medical (NSDQ:HNSN) announced immediate commercial launch upon receiving FDA clearance for its Magellan robotic system and accessories for peripheral vascular interventions.
The system was cleared for providing navigation to anatomical targets and a conduit for manual device implantation while keeping physicians away from a potentially harmful radiation source.
MassDevice.com +3 | The top 3 med-tech stories for April 11, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Court OKs Hansen Medical settlement with shareholders
Hansen Medical (NSDQ:HNSN) said a California court approved its deal to settle a set of lawsuits filed against by shareholders over a 2009 financial restatement for $300,000.
Boston Scientific CFO Jeffrey Capello joins board of OvaScience | Personnel Moves
Boston Scientific (NYSE:BSX) executive vice president and chief financial officer Jeffrey Capello joined the board of directors at OvaScience, a Boston, Mass.-based start up developing infertility treatments.
Capello began working at Boston Scientific in 2008, landing the CFO seat in 2010. He oversees the company’s global finance, information systems, business development and corporate strategy functions.